Olga I Butranova
Overview
Explore the profile of Olga I Butranova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butranova O, Terekhina E, Zyryanov S, Gildeeva G, Abramova A, Kustov Y, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767557
Background/objectives: Pulmonary fibrosis (PF) results in a progressive decline of lung function due to scarring. Drugs are among the most common causes of PF. The objective of our study was...
2.
Emelyanenko A, Omran F, Teplonogova M, Chernukha M, Avetisyan L, Tselikina E, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38674057
A method has been proposed for creating an operationally durable copper coating with antimicrobial properties for the buttons of electrical switches based on the gas dynamic spray deposition of copper...
3.
Butranova O, Ushkalova E, Zyryanov S, Chenkurov M, Baybulatova E
Biomedicines
. 2023 Jun;
11(6).
PMID: 37371728
Infections are important factors contributing to the morbidity and mortality among elderly patients. High rates of consumption of antimicrobial agents by the elderly may result in increased risk of toxic...
4.
Butranova O, Ushkalova E, Zyryanov S, Chenkurov M
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979919
Neonatal Infections are among the most common reasons for admission to the intensive care unit. Neonatal sepsis (NS) significantly contributes to mortality rates. Empiric antibiotic therapy of NS recommended by...
5.
Zyryanov S, Ushkalova E, Kondratyeva E, Butranova O, Kondakova Y
Biomedicines
. 2022 May;
10(5).
PMID: 35625789
(1) Background: Ciprofloxacin (CPF) is widely used for the treatment of cystic fibrosis, including pediatric patients, but its pharmacokinetics is poorly studied in this population. Optimal CPF dosing in pediatric...